Pds Biotechnology Corp (PDSB)
$4.02
+0.24
(+6.49%)▲
Insights on Pds Biotechnology Corp
Vs NVO
In the last 1 year, Novo Nordisk A/s has given 51.1% return, outperforming this stock by 95.1%
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 236.5% return, outperforming this stock by 258.5%
Performance
- $3.57$4.30$4.02
11.19%
Downside
Day's Volatility :16.98%
Upside
6.51%
- $2.59$10.27$4.02
35.57%
Downside
52 Weeks Volatility :74.78%
Upside
60.86%
Returns
| Period | Pds Biotechnology Corp | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | -28.23% | -1.1% | 0.0% |
6 Months | -18.99% | 11.2% | 0.0% |
1 Year | -43.99% | 7.0% | 0.8% |
3 Years | -13.22% | 14.9% | -22.1% |
Highlights
Market Capitalization | 119.6M |
Book Value | $0.79 |
Earnings Per Share (EPS) | -1.39 |
Wall Street Target Price | 14.4 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -39.45% |
Return On Equity TTM | -122.46% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -43.0M |
Diluted Eps TTM | -1.39 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.48 |
EPS Estimate Next Year | -1.61 |
EPS Estimate Current Quarter | -0.44 |
EPS Estimate Next Quarter | -0.44 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 258.21%
Technicals Summary
Sell
Neutral
Buy
Pds Biotechnology Corp is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Pds Biotechnology Corp | 14.05% | -18.99% | -43.99% | -13.22% | -44.07% |
 Moderna, Inc. | 15.21% | 69.71% | -8.11% | -23.64% | 414.32% |
 Regeneron Pharmaceuticals, Inc. | 3.36% | 17.89% | 28.96% | 93.09% | 194.82% |
 Novo Nordisk A/s | -0.13% | 25.09% | 51.14% | 233.74% | 425.88% |
 Vertex Pharmaceuticals Incorporated | 1.49% | 8.83% | 19.22% | 92.69% | 142.73% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Pds Biotechnology Corp | NA | NA | NA | -1.48 | -1.22 | -0.39 | NA | 0.79 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.22 | -0.29 | -0.12 | NA | 36.27 |
Regeneron Pharmaceuticals, Inc. | 26.04 | 26.04 | 1.46 | 45.0 | 0.16 | 0.08 | NA | 242.47 |
Novo Nordisk A/s | 47.43 | 47.43 | 2.4 | 3.35 | 0.88 | 0.23 | 0.01 | 23.9 |
Vertex Pharmaceuticals Incorporated | 28.81 | 28.81 | 0.53 | 16.75 | 0.23 | 0.13 | NA | 68.22 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Pds Biotechnology Corp | Buy | $119.6M | -44.07% | NA | 0.0% |
Moderna, Inc. | Buy | $41.7B | 414.32% | 24.73 | -68.84% |
Regeneron Pharmaceuticals, Inc. | Buy | $99.5B | 194.82% | 26.04 | 30.14% |
Novo Nordisk A/s | Buy | $562.8B | 425.88% | 47.43 | 36.03% |
Vertex Pharmaceuticals Incorporated | Buy | $103.6B | 142.73% | 28.81 | 36.68% |
Institutional Holdings
BlackRock Inc
5.13%Vanguard Group Inc
4.11%Geode Capital Management, LLC
1.73%State Street Corporation
1.51%TANG CAPITAL MANAGEMENT LLC
1.09%Jefferies Financial Group Inc
1.09%
Corporate Announcements
Pds Biotechnology Corp Earnings
Pds Biotechnology Corp’s price-to-earnings ratio stands at None
Read More
Company Information
pds biotechnology is a clinical stage biopharmaceutical company developing the next-generation of simpler, safer and more effective immunotherapies for cancer and infectious diseases. pds biotechnology’s proprietary versamune® platform vector is based on synthetic and biodegradable lipids which possess a very specific structure and positive charge. the lipids form nanoparticles which activate and are taken up very efficiently by the immune system. the therapeutic product consists of versamune® formulated with a harmless form of the protein or disease-causing agent associated with the particular disease (the antigen) which our immune systems can recognize and respond to. this antigen could be a unique protein expressed only in the cancer cells and not in healthy cells, or it could be a specific viral protein(s) from an infectious virus for example. pds is in the process of completing its first phase 1 human clinical trial in 2015 for pds0101, and has initiated design and preparati
Organization | Pds Biotechnology Corp |
Employees | 25 |
CEO | Dr. Frank K. Bedu-Addo Ph.D. |
Industry | Biotechnology |
